Solid tumor

  1. A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
    This trial is a first-in-man study for a new type of antidote, which is thought to boost the immune system's attack against cancerous cells. The first phase tests the safety of the drug at different doses. The trial accepts patients who have an intestinal cancer, a liver cancer, or a melanoma that has progressed during standard treatment.
    Primary researcher: Panu Jaakkola

  2. Origin of tumor unknown (NUD)
    A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have received three cycles of platinum douplet chemotherapy

    The purpose of the study is to assess the effectiveness and safety of selective drugs or immune therapy chosen based on gene profiling in comparison with platinum-based cytostatic therapy in cancer patients for whom the original tumor location is unknown, and who have received two different platinum-based cytostatic drugs for three treatment cycles.
    Primary researcher: Pia Suonpää

  3. An open label, multicohort, phase II study of MPDL3280A in advanced solid tumors
    The purpose of the study is to outline the advantages and disadvantages of the drug MPDL3280A in the treatment of far-advanced solid tumors. MPDL3280A is a drug that is currently in the clinical trial stage. MPDL3280A is an antibody (protein created by the immune system).
    Primary researcher: Katriina Peltola

  4. A phase Ib/II open label, multicentre study of PDR001 in combination with MCS110 in patients with advanced malignancies
    Two compounds called “MCS110” and “PDR001” are administered in the trial as a combination therapy. Both trial compounds are antibodies, which recognise a certain protein in the system. The goal of the therapy is to enable the patient's own immune system to attack and destroy the cancer cells. The study aims to identify the correct dosage while at the same time researching the effectiveness and safety of the combination therapy.
    Primary researcher: Panu Jaakkola

  5. A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
    The purpose of the study is to assess the safety, tolerability and effectiveness of anti-LAG-3 antibody administered either by itself or together with nivolumab in patients who are diagnosed with an advanced solid tumor.
    Primary researcher: Katriina Peltola
 

 Contact Information

 
haluantutkimuspotilaaksi@hus.fi
tel. +358 50 427 0680